Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study
Open/View files
Date
2015
Author(s)
Tikk, Kaja
Sookthai, Disorn
Fortner, Renée T
Johnson, Theron
Rinaldi, Sabina
Romieu, Isabelle
Tjønneland, Anne
Olsen, Anja
Overvad, Kim
Clavel-Chapelon, Françoise
Baglietto, Laura
Boeing, Heiner
Trichopoulou, Antonia
Trichopoulos, Dimitrios
Masala, Giovanna
Krogh, Vittorio
Tumino, Rosario
Ricceri, Fulvio
Mattiello, Amalia
Agudo, Antonio
Menéndez, Virginia
Sánchez, María-José
Amiano, Pilar
Chirlaque, Maria-Dolores
Barricarte, Aurelio
Bueno-de-Mesquita, HBas
Monninkhof, Evelyn M
Onland-Moret, N Charlotte
Andresson, Anne
Sund, Malin
Weiderpass, Elisabete
Khaw, Kay-Tee
Key, Timothy J
Travis, Ruth C
Merritt, Melissa A
Riboli, Elio
Dossus, Laure
Kaaks, Rudolf
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Tikk, K., D. Sookthai, R. T. Fortner, T. Johnson, S. Rinaldi, I. Romieu, A. Tjønneland, et al. 2015. “Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.” Breast Cancer Research : BCR 17 (1): 49. doi:10.1186/s13058-015-0563-6. http://dx.doi.org/10.1186/s13058-015-0563-6.
Abstract
Introduction: The relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention. Methods: We analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched control subjects. Results: We found a significant positive association between higher circulating prolactin levels and risk of in situ breast cancer among all women [pre-and postmenopausal combined, ORlog2 = 1.35 (95% CI 1.04-1.76), Ptrend = 0.03]. No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal status (Phet = 0.98) or baseline HT use (Phet = 0.20), although the observed association was more pronounced among postmenopausal women using HT compared to non-users (Ptrend = 0.06 vs Ptrend = 0.35). In subgroup analyses, the observed positive association was strongest in women diagnosed with in situ breast tumors <4 years compared to ≥4 years after blood donation (Ptrend = 0.01 vs Ptrend = 0.63; Phet = 0.04) and among nulliparous women compared to parous women (Ptrend = 0.03 vs Ptrend = 0.15; Phet = 0.07). Conclusions: Our data extends prior research linking prolactin and invasive breast cancer to the outcome of in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ breast cancer.
Other Available Sources
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
Collection